Lonza announced the completion of the divestment of its Ploermel and Edinburgh sites to NextPharma.

Gordon Bates, President and Head of Small Molecules, Lonza said, “The strategic divestment of our Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies. In this context, as we close the divestment process, we are confident that NextPharma is well placed to develop and grow both sites to their full potential.”

Peter Burema, CEO, NextPharma said, “We are very excited at adding two new centers of excellence, at Ploermel and Edinburgh, to NextPharma’s manufacturing network, allowing us to further broaden our technology offering for both our existing and new customers. These technologies, combined with the know-how and expertise of the employees at both sites, will provide additional solutions for drug formulations which will benefit patients across the world. On behalf of the whole NextPharma team, I welcome our new colleagues, and together we look forward to continuing to further develop and grow NextPharma as a leading and well-respected European CDMO.”

The agreement between both parties was previously announced on 19 January 2021.

Announcement on Obtaining the Approval of the Joint Restructuring of Sinochem and ChemChina